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used as an adjunct to laparoscopic primary removal of myomas in
women wishing to improve pregnancy outcomes.
© 2016 The Authors. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The clinical trials are conducted in a series of stages, called phases, with each phase being designed
to answer a separate research aspect.
I. Preclinical, nonclinical studies. These include studies with a duration of 2e3 years on different
models such as cultured tissue and animals. The safety examination includes the study of toxicology,
pharmacology, biochemistry, mutagenicity, and pharmacokinetics (absorption, drug distribution,
metabolism, and excretion). For the ﬁrst-in-human studies, the early nonclinical examinations should
provide sufﬁcient information on the initial human dose and safe duration of exposure as well as
produce data on the physiological and toxicological effects of the investigational device [1].
Preclinical phase for ADBLOCK System
Preclinical studies for ADBEE were undertaken in accordance with standards issued by the Inter-
national Organization for Standardization (ISO), harmonized European standards (EN) [2], and the
Food and Drug Administration (FDA) Guidance for Resorbable Adhesions Barrier Devices (FDA, US Food
and Drug) [3]. These studies have provided evidence of both the safety and efﬁcacy of the ADBLOCK
system in reducing adhesions in standard animal models [4]. Although novel compounds, the con-
stituent elements are well-established agents for use in clinical practice.
The safety and efﬁcacy of ADBLOCK is based on the results obtained from the biocompatibility and
pharmacokinetic studies, in vitro testing, manufacturing and control data, in vivo testing, sterilization
validation, and stability testing. A comprehensive risk review for ADBLOCK has also been performed in
accordance with EN ISO 14971. The details of the risk management review are described in a risk
management report. This concluded that all knownpossible risks associatedwith thematerials, design,
manufacturing process, and clinical use of the system have been considered and made acceptable by
taking into account requirements stipulated in applicable harmonized standards or international
standards during design, production, and testing, or by putting in place the necessary precautions,
warnings, or contraindications in the information provided with the device.
Biochemical safety
ADBLOCK Adhesion Barrier is an experimental site-speciﬁc sprayable adhesion barrier gel based on
a dextrin polymer, which is currently being investigated as an adhesion-reducing agent for use in
patients undergoing abdominopelvic surgery as an adjunct to surgery, with the aim of reducing the
incidence, severity, and extent of adhesion formation postoperatively.
A similar existing dextrin polymer (icodextrin) has recently been approved in Europe and the USA as
an anti-adhesion solution (Adept®), with an excellent long-term safety record from its global use as an
intraperitoneal dialysate as well as an anti-adhesion agent. The anti-adhesion solution Adept is
currently the most widely used anti-adhesion agent available. Although it has been shown to be safe
and effective in reducing adhesions [5], recent research suggests other advantages offered by site-
speciﬁc gels such as ADBLOCK [6].
The polymer system in ADBLOCK is a novel compound based on existing and established agents.
It contains one precursor comprising an NHS (N-hydroxysuccinimide)-modiﬁed carboxymethyl
dextrin polymer with trehalose (alpha linked disaccharide), which has been used in various
pharmaceutical biopharmaceutical agents (including the monoclonal antibody formulations tras-
tuzumab and bevacizumab e Herceptin® and Avastin®) [7] and is being investigated for its anti-
adhesion potential in ocular surgery. The other precursor is a standard alkaline sodium hydrogen
Figure 1. ADBLOCK gel composition.
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polymers link to form a hydrogel barrier within 10 s, a hydrogel predominantly of dextrin polymers
and microbubbles consisting of 60e95% water with solids (Fig. 1). These microbubbles within the
gel provide an opaqueness that allows easier visualization of the gel placement, thickness, and
coverage. This formulation may have advantages over some other available gel agents that
require the use of colorants for visualization as well as reformulation due to issues of tissue
reactogenicity [8].Figure 2. Visibility of the gel (upper: before spraying; lower: after spraying).
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temporary barrier that prevents ﬁbrin deposits from the damaged mesothelium from forming a bridge
and interconnecting the opposing tissue surfaces (Fig. 2).
A pharmacokinetic study on a radiolabelled product in a rabbit model showed that the
ADBLOCK gel remained visibly in the abdominal cavity about 1 day after spraying into the rabbit
abdominal cavity and was absorbed from the abdominal cavity within 3 days after spraying. This
short residence time not only provides coverage during the critical period of adhesion formation
[9] but also ensures the agent is not retained after this period, similar to other agents [10,11]. The
agent is removed from the abdominal cavity through the lymphatic system and absorbed into the
bloodstream where it is hydrolyzed by the enzyme amylase and then cleared through the
kidneys.
II. Clinical studies. During research, three ethical principles should be respected: the safety of
the human subjects, obligation to do no harm with minimum injuries for the patients, and an
equitable proportion of advantages and disadvantages of the research. The principles for protecting
human subjects, which represent an essential requirement for clinical trials, originate from the
Declaration of Helsinki, and they should be strictly followed when conducting product in-
vestigations in humans [1].
The clinical development of an investigational device involves the following four temporal phases:
 Phase I (human pharmacology): This phase begins with the initial use of the investigational product
in human subjects, involving one or a combination of the following: estimation of initial safety and
tolerability, pharmacokinetics, pharmacodynamics, and early measurement of drug action.
 Phase II (therapeutic exploratory): The primary objective of this phase is to explore the therapeutic
efﬁcacy in patients.
 Phase III (therapeutic conﬁrmatory): The primary aim of this phase is to demonstrate or conﬁrm the
therapeutic beneﬁts of the investigational device.
 Phase IV (therapeutic use): This phase begins after the investigational device is approved [2].
A. The safety of clinical trial subjects
According to International Conference on Harmonisation-Good Clinical Practice Guidelines and ISO
14155, all clinical studies should be monitored with the aim of protecting patients from preventable
harm. The safety monitoring is directed toward the early detection and prevention of rare, severe
adverse reactions [2]. Clinical investigators are required to report all serious adverse events (SAEs) to
the sponsor, regardless of being device related.
1. Adverse event (adverse experience)
An adverse event (AE) is any undesirable experience (sign, symptom, illness, abnormal laboratory
value, or other medical event) of a patient that appears or worsens during the study, regardless of its
relation to the product being studied or drug regimen prescribed as part of the clinical investigational
plan. Failure of the device may be considered an AE if an undesirable experience occurs. The clinical
investigators are required to report the AEs to the sponsor as soon as possible without unjustiﬁable
delay. The investigator should record the nature, severity, treatment, and outcome of the AE, as well as
determine the event's relationship to the investigational products.
The severity of each AE can be deﬁned as follows:
- Mild: This constitutes awareness of a sign or symptom that does not interfere with the patient's
usual activity or is transient, which is resolved without treatment and presents no sequelae.
- Moderate: This interferes with the patient's usual activity and/or requires symptomatic treatment.
- Severe: This includes symptom(s) causing severe discomfort and signiﬁcantly affecting the patient's
usual activity, requiring treatment.
The relationship of the AE to the use of the studied product/device can be deﬁned as follows:
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to an underlying or concurrent illness or the effect of another device or drug.
- Unlikely: An AE has little or no temporal relationship to the study device and/or a more likely
alternative etiology exists.
- Possible: The temporal sequence between drug or device application and the event likely point to
their relationship, or the patient's condition or concomitant therapy could have caused the AE.
- Probable: The temporal sequence is relevant or the event declines upon completion/removal of the
device application or the event cannot be reasonably explained by the patient's condition.
- Highly probable: The temporal sequence is relevant and the event declines upon completion of the
device application, or the event reappears when device application is repeated.
2. Serious adverse event
For each AE observed, the investigator must determine whether the event meets the deﬁnition of a
“serious” adverse event (SAE). An event is considered serious under the following conditions:
a) Death
b) A serious deterioration in the health of the subject that
 resulted in a life-threatening illness or injury
 resulted in permanent impairment of a body structure or a body function
 required patient hospitalization or prolongation of existing hospitalization
 resulted in medical or surgical intervention to prevent permanent impairment to body structure
or a body function
c) Fetal distress, fetal death, or a congenital abnormality or birth defect.
The clinical investigators should report all SAEs to the sponsor as soon as possible without unjus-
tiﬁable delay.
3. Device malfunction
A device malfunction is deﬁned by the failure of a device to meet its performance speciﬁcations or a
performance contrary to the labeled indication. In the case of failure of a device, the investigator must
return the device to the sponsor.
4. Unanticipated serious adverse device effects
An unanticipated serious adverse device effect is deﬁned as an effect that has not been identiﬁed by
its nature, incidence, severity, or outcome in the clinical investigational plan accompanying the risk
analysis report. Sites are requested to report promptly any device malfunction and unanticipated
adverse device effect.
5. Outcome categorization
Outcomes may be classiﬁed as resolved, unresolved, resolving, resolved with sequelae, death, or
unknown.
B. ADBLOCK system in ﬁrst-in-human clinical trial (phase I)
Material and methods
A ﬁrst-in-human clinical trial based on a randomized, controlled multicentric study was conducted
to assess the safety, manageability, and usability of the ADBLOCK system when used as an adjunct to
laparoscopic surgery for the primary removal of myomas in women wishing to improve pregnancy
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Gynecology, Pius-Hospital Oldenburg; Department of Obstetrics and Gynecology at Johanna-Etienne-
Clinic, Neuss; and the Clinic for Minimal Invasive Surgery, Berlin-Zehlendorf, Germany.
The study involved single-blind subjects, and the investigators were blinded to the assignment of
treatment groups until completion of uterine suturing and prior to removal of the endoscope.
Participants: Preoperatively, the patients met the following inclusion criteria: generally healthy
women aged between 18 and 45 years with negative pregnancy test results before entry into the study,
who have not completed their childbearing and who are undergoing primary (“virgin”) laparoscopic
myomectomy [12] with the aim of improving pregnancy outcomes. The patients provided voluntary
written informed consent and were willing to use adequate forms of contraception for 12 weeks
following the surgery. The pre- and intraoperative exclusion criteria were as follows: use of
gonadotropin-releasing hormone (GnRH) agonist/antagonist treatment in the 4weeks prior to the study,
breast-feeding, previous bowel surgery, pelvic malignancy, pelvic inﬂammatory disease, an immuno-
compromised condition, or intraoperative use of corticosteroids. Patients requiring a conversion to
laparotomy or any unplanned surgery with opening of the bowel or urinary tract intraoperatively and
patients with extensive pelvic adhesions (AFS severe adhesion score) or frozen pelvis were excluded.
Study design: The patients were randomized into two groups: the ADBLOCK arm with 21 patients
and the surgery-only arm with 11 patients. As a primary end point, the safety was evaluated by
assessing the AEs in the ADBLOCK and surgery-only groups up to 28 days to conﬁrm that the use of
ADBLOCK is as safe as surgery alone. The manageability and usability of the device were analyzed as
secondary end points of the study (Fig. 3).
The study ﬂow is represented in Figs. 4 and 5.
Results
The preoperative demographic ﬁndings are presented in Table 1. The 32 patients were women
between the ages of 18 and 45 years, who underwent a primary laparoscopic myomectomy with the
aim of improving the fertility outcomes. The patients were randomized into two groups: the ADBLOCK
armwith 21 patients and the surgery-only arm of 11 patients. The mean agewas 34.9 ± 5.4 years in theFigure 3. Study design.
Figure 4. ADBEE study ﬂow.
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the ADBLOCK group and 67.1 ± 15.0 kg for the control group. The mean height of the patients was
169.0 ± 6.5 cm in the ADBLOCK arm and 166.4 ± 15.0 cm in the surgery-only arm. The patients were
general healthy, and the most common symptoms and signs in the both groups were abdominal pain,
tenderness, and abdominal discomfort and distension.
The intraoperative ﬁndings are provided in Table 2. We used a standardized surgical technique for
all patients, with the number of uterine incisions varying from one to a maximum of three. The average
length of the incisionwas 45.2± 37.0mm in the studied group and 26.0 ± 15.1mm in the control group.
In most of the patients, the blood loss reported during the surgery was normal or less than usual, with
no statistically signiﬁcant difference between both groups (p ¼ 0.513). The volume of lactated Ringer's
solution (LRS) used in the surgery was 404.3 ± 170.0 ml for the ADBLOCK arm and 365.5 ± 135.6 ml for
surgery-only arm. The mean surgery time was 62.1 ± 19.3 min, ranging from 38 to 115 min in the
studied group. A similar duration of surgery was observed in the control group, with an average of
56.7 ± 26.3 min, ranging from 25 to 116 min, and a p-value of 0.520, showing no statistically signiﬁcant
difference between the groups. The adhesions were present in seven patients of the ADBLOCK group,
with adhesiolysis required in six patients, and in ﬁve patients of the surgery-only arm, with lysis
required in one patient.
No signiﬁcant difference was detected between the ADBLOCK arm and surgery-only arm in terms of
the primary end point in the both groups, the number of patients reporting an AE (Table 3).
The AEs reported in our series are presented in Table 4, with some patients experiencing more than
one event. The most AEs were postoperative pain, nausea and vertigo, headache, hyper- or dysmen-
orrhea, and allergic reactions (Table 4).
An SAE was reported in two patients of the ADBLOCK group and in one patient of the surgery-only
arm. A surgery-related AE was observed in six patients of the studied group and four patients of the
control group. No device-related AEs were reported in our series (Table 5).
Discussion
Adhesions are the most frequent complication of abdominopelvic surgery, occurring in 60e90% of
the patients following a major operative procedure [13]. The postoperative adhesions are associated
with high morbidity and mortality, as they are the leading cause of intestinal obstruction, reduced
Figure 5. ADBEE study ﬂow.
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sidewall following a gynecological surgery may involve the bowel, omentum, or adnexa, resulting in
pelvic pain, bowel obstruction, dyspareunia, or residual ovary syndrome [14]. Postoperative adhesions
may also complicate future surgeries, by prolonging the duration of operation and increasing the risk ofTable 1
Baseline characteristics of patients.
ADBLOCK arm
N ¼ 21
Surgery-only arm
N ¼ 11
p-value
Age (years) 34.9 ± 5.4 35.6 ± 3.6 0.706
Height (cm) 169.0 ± 6.5 166.4 ± 9.5 0.361
Weight (kg) 68.3 ± 21.9 67.1 ± 15.0 0.875
Preoperative status
Pain (general) 1.25 ± 1.51 1.27 ± 2.41 0.971
Abdominal pain 1.67 ± 1.78 1.55 ± 2.42 0.868
Abdominal tenderness 1.09 ± 1.53 1.36 ± 2.16 0.675
Abdominal discomfort 1.66 ± 2.20 2.14 ± 2.93 0.610
Abdominal distension 1.63 ± 2.62 1.73 ± 2.61 0.920
General well-being 1.38 ± 1.59 1.45 ± 1.92 0.912
Table 2
Main surgical characteristics.
ADBLOCK arm
N ¼ 21
Surgery-only arm
N ¼ 11
p-value
Uterine incisions: 1.2 ± 0.5 1.2 ± 0.6 0.789
- Number (mean, range) (min 1, max 3) (min 1, max 3)
- Length (mm) 45.2 ± 37.0 mm 26.0 ± 15.1 mm 0.133
Blood loss
- Normal 13 (61.9%) 5 (45.5%) 0.513
- Less than usual 7 (33.3%) 5 (45.5)
- More than usual 1 (4.8%) 1 (9.1%)
Volume of LRS used in surgery 404.3 ± 170.0 365.5 ± 135.6 0.518
Duration of surgery (min, range) 62.14 ± 19.3
(38e115 min)
56.7 ± 26.3
(25e116 min)
0.520
Adhesion present 7 (33.3%) 5 (45.5%) 0.703
Lysing undertaken 6 (28.6%) 1 (10.0%) 0.379
Table 3
Primary endpoint e ADBLOCK arm showed non-inferiority compared to surgery only arm.
ADBLOCK arm
N ¼ 21
Surgery only arm
N ¼ 11
p-value
Number (%) of patients reporting an adverse event 13 (62%) 9 (81%) 1.000
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has been conducted on operative procedures, with a focus on prevention through meticulous surgical
technique. Despite several surgical advances including laparoscopy, the risk of adhesion-related
complications remains the same, regardless of the route used: laparoscopical or open surgery [16].
Adhesiolysis has long been the treatment of choice for the management of adhesions, but it involves a
high risk of reformation, and the adhesions that reform after lysis tend to bemore dense and severe [9].
In recent years, considerable research has been devoted to better understanding the pathophysi-
ology of adhesions from their formation to their epidemiology, cost implication, and prevention, in
order to improve the outcomes for patients and to minimize the impact of many adhesion-related
complications [17].
The ﬁrst step in reducing the risk of adhesion formation should be the use of a meticulous surgical
technique such as performing scrupulous hemostasis and diligently using cauteries, reducing the
duration of the surgery, diminishing the pressure and duration of pneumoperitoneum in laparoscopy,
minimizing the risk of infection, and avoiding the use of foreign bodies [9]. Many inherited factors are
involved in the organization of adhesions that cannot be prevented by an accurate, meticulous surgical
technique [9,18]. Studies on prevention of adhesions have been unsuccessful, because of the
biochemical complexities and the as yet unclear etiology of the formation of adhesions, as well as due
to the lack of good predictive animal models [19]. Moreover, reports over time have pointed to the
failure or limited use of traditional prevention strategies, until the recent introduction of newer agents
[9,10]. Even if a careful surgical technique is adopted, many of the injuries that cause adhesions are
common to such surgeries and cannot be avoided [20,21]. Moreover, peritoneal repair after surgery hasTable 4
Adverse events by type.
(Safety population)
(up to 28 days)
ADBLOCK arm
N ¼ 21
Surgery only arm
N ¼ 11
p-value
Post-procedural pain 6 (28.6%) 5 (45.5%) 0.442
Nausea & Vertigo 2 (9.5%) 2 (18.1%) 1.000
Headache 2 (9.5%) 0 (0%) 1.000
Hyper/Dysmenorrhea 2 (9.5%) 1 (9.1%) 1.000
Allergy 1 (4.8%) 1 (9.1%) 1.000
Table 5
Adverse events by treatment group.
(Safety population)
(up to 28 days)
ADBLOCK arm
N ¼ 21
Surgery only arm
N ¼ 11
p-value
Number (%) of patients reporting a serious adverse event 2 (9.5%) 1 (9.1%) 1.000
Number (%) of patients reporting surgery-related adverse event 6 (28.57%) 4 (36.36%) 1.000
Number (%) of patients reporting device-related adverse event 0 (0.0%) NA NA
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but not prevent the formation of adhesions, so postoperative adhesions remain very common [22]. The
adjuvant therapy for adhesion prevention have become mandatory. Several adjuvant agents and drugs
have been used to prevent adhesions, including pharmacological agents and physical barriers. Many
agents have been used to prevent the formation of postoperative adhesions, such as anti-inﬂammatory
drugs (nonsteroidal anti-inﬂammatory drugs (NSAIDs)), antibiotics, corticosteroids, and ﬁbrinolytics
[23,24]. The efﬁcacy of NSAIDS in preventing adhesions was debatable [25]. The preventive effect of
corticosteroids is also inferior, associated with many side effects due to an immunosuppressive reac-
tion. Given their effect of reversing ﬁbrin deposition, ﬁbrinolytics may lead to poor wound healing and
a high risk of bleeding as well [26]. The less reduction of adhesion and the safety concerns for some of
these agents have limited the use of pharmacological regimens as anti-adhesion agents [24,25,27].
Currently, the only available adjuncts that can prevent the formation of adhesions are physical
separators [9,10]. These agents effectively separate the traumatized peritoneal area for approximately
3e5 days after surgery, the critical period of adhesion development [28]. This separation can be achieved
by the use of intraperitoneal instillates and site-speciﬁc mechanical barriers. Intraperitoneal instillates
(crystalloid solutions) include Ringer's lactate, dextran 70 (Hyskon®), Intergel®, Sepracoat®, and Adept®.
Site-speciﬁc barriers include Preclude®, Interceed®, Sepraﬁlm®, SprayGelTM, Hyalobarrier®, and Surgi-
wrapTM [9,10]. An ideal adhesion barrier has the following features: sufﬁcient half-life to cover the
peritoneal healing period at the peritoneal cavity, provision of effective tissue separation, activity and
efﬁcacy even in a blood environment, absorbability and metabolizability without a proinﬂammatory
tissue reaction, absence of adverse effect on wound healing, and inhibition of bacterial overgrowth.
A valuable anti-adhesion agent is recognized for its ability to not only reduce the development of
adhesions after adhesiolysis but also reduce the incidence of associated complications such as small
bowel obstruction [29e31] and improve pregnancy outcomes [32,33]. Patients undergoing open or
laparoscopic myomectomy are at a particular risk of postoperative adhesions, which may compromise
successful fertility outcomes and pose long-term risks including small bowel obstruction and reo-
perative complications [34].
The ADBLOCK system has been formulated and presented for the use in both laparotomy and
laparoscopy. Given the advances in minimally invasive surgery such as faster recovery and less surface
scarring, laparoscopy is preferred for many procedures. However, the risk of adhesions remains high,
thus making anti-adhesion agents that are easy to manage in laparoscopic surgery as well as safe and
effective promising candidates [10].
The ADBLOCK system can be assembled quickly and prepared in the theater within 10 min, and it
does not require any special equipment. Preclinical research indicates its safety and efﬁcacy, and it has
been successfully applied in a porcine model (internationally recognized training model for laparos-
copy) with minimal training [4].
The risk of adhesions is high following posterior myomectomy [6,35e37]. The duration of surgical
procedure also plays an important role, with a duration of operation >90 min leading to a higher
demonstrable adhesion potential [38]. CO2 pneumoperitoneummay have an adhesiogenic effect due to
induced intraperitoneal acidosis [39e41], or due to the desiccation of the mesothelium, in the absence
of moistening [42]. Prolonged pneumoperitoneum is associated with peritoneal hypoxia, an important
cofactor in adhesion formation, together with mesothelial injuries [43,44]. Given the adhesiogenic risk
of prolonged pneumoperitoneum [9,10], the ADBEE study focused particularly on the main cohort of
patients with pneumoperitoneum 90 min.
Other factors to be considered for their possible impact on successful outcomes are the size and
number of the myomas, blood loss during the surgery, suture type used, operating technique, and the
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various covariates may affect the adhesion-related outcomes, with important intercenter, intracenter,
and intersurgeon variables that need to be accounted for. In order to eliminate different covariates that
may increase the risk of adhesion formation, a standardized surgical techniquewas proposed for all the
patients, in close accordance with the research ﬁndings on the impact of surgery on myomectomy
outcomes: insufﬂation pressure of 10e15 mm Hg, incision on the ventral axis of the myoma using
monopolar diathermy, continuous suturing of the uterus with a 2/0 suture device, and the use of LRS as
irrigant ﬂuid, which must be evacuated before the application of ADBLOCK.
The purpose of the present paper was to provide an example and deﬁnition of safety standards that
can be easily and practically applied for every ﬁrst-in-human clinical study in order to improve the
safety of the patients.
Before a clinical study is started, several preliminary events are amenable. The preclinical studies
must be completely fulﬁlled, and data on the physiological and toxicological effects of the investiga-
tional product should be made available. The patient must provide informed consent only after being
apprised by a trained, qualiﬁed physician, the goal of the consent being to protect the participants. The
physician should provide all of information about the study, ascertain that the subjects understand the
potential risks and beneﬁts, and notify the participants of their right to leave the study at any point.
In order to obtain the best safety standard for the patients, the investigators and all medical
personnel involved in the study should ensure the following are observed: the ethical principles
originated from the Declaration of Helsinki, the safety of the subjects as the most important and
priority factor, and rigorous evaluation of the anticipated risks or inconveniences, with the study being
initiated only when the expected beneﬁts justify the risks. A clear detailed protocol is also mandatory
in order to obtain the best evidentiary support for the study. The data obtained from the clinical trials
must be recorded and stored, and these should be easily available for veriﬁcation, validation, and
interpretation, with highly conﬁdential protection of the clinical subjects. The product to be investi-
gated should be stored and used in line with the principle of GMP (good manufacturing practice). The
safety reporting plays a critical role in organizing a clinical trial. All SAEs should be reported imme-
diately to the sponsor, regardless of being device related, according to the reporting requirements. All
AEs require detailed and prompt written reports.Conclusion
The ﬁrst-in-human clinical trial of the ADBEE study has reached its primary end point with respect
to safety versus surgery alone. The rate of AEs was similar in the two study arms, with no device-
speciﬁc safety concerns. Further ongoing follow-up up to 2 years in the study and/or planned
studies will address the efﬁcacy of ADBLOCK in preventing adhesions.Practice Points
1. Preclinical studies
2. Biochemical safety
3. Clinical studies with three ethical principles:
- Safety of the human subjects
- Obligation to do no harm
- Equitable proportion of advantages and disadvantages.
Research Agenda
Follow-up up to 2 years in the study and/or planned studies will address the efficacy of
ADBLOCK in preventing adhesions.
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